Compounds > danazol
Page last updated: 2024-08-23

danazol and tacrolimus

danazol has been researched along with tacrolimus in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Fung, JJ; McCauley, J; Rybka, W; Scantlebury, VP; Shapiro, R; Starzl, TE; Venkataramanan, R; Warty, VS1
An, ZY; Cai, X; Fu, HX; He, Y; Huang, XJ; Wang, CC; Wu, J; Zhang, XH; Zhu, XL1

Reviews

1 review(s) available for danazol and tacrolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for danazol and tacrolimus

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
FK 506 interaction with danazol.
    Lancet (London, England), 1993, May-22, Volume: 341, Issue:8856

    Topics: Adult; Danazol; Drug Interactions; Female; Humans; Tacrolimus

1993
Tacrolimus prevents complement-mediated Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and pyroptosis of mesenchymal stem cells from immune thrombocytopenia.
    British journal of haematology, 2023, Volume: 202, Issue:5

    Topics: Adiponectin; Complement C3; Danazol; Fatty Acids; Humans; Inflammasomes; Mesenchymal Stem Cells; NLR Family, Pyrin Domain-Containing 3 Protein; NLR Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrin Domain; Pyroptosis; Tacrolimus; Thrombocytopenia

2023